<DOC>
	<DOCNO>NCT01598987</DOCNO>
	<brief_summary>This study design assess evolution renal function collect efficacy , safety , tolerability data everolimus co-exposure reduce CNI paediatric liver transplant recipient .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Everolimus Combination With Reduced Exposure Cyclosporine Tacrolimus Paediatric Liver Transplant Recipients .</brief_title>
	<detailed_description>Study complete ( active ongoing longer recruit since December 2014 ) . The study Data Monitoring Committee meeting communicate Novartis follow safety finding study population : high rate premature discontinuation study medication , high rate post-transplant lymphoproliferative disease high rate relate serious infection lead hospitalization . In light safety finding , Novartis follow DMC recommendation discontinue study medication age group stop enrol new patient study ( regardless age ) .</detailed_description>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Key Signed informed consent parent legal guardian ( ) prior patient participation study . Paediatric liver transplant recipient age great equal 1 month young 18 year age . Paediatric recipient early 1 month late 6 month liver transplantation . Key Patients hepatobiliary malignancy and/or patient transplant due fulminant hepatitis /acute liver failure . Presence thrombosis major hepatic artery , major/reconstructed hepatic vein , portal vein inferior vena cava time prior start study drug . Patients serum creatinine value &gt; 2 time agerelated ULN Baseline receive renal replacement therapy within one week prior start study drug patient confirm spot urine protein/creatinine ratio indicate urinary protein excretion &gt; 500 mg/m2/24 hr , Baseline . Patients clinically significant systemic infection and/or critical care set require life support measure mechanical ventilation , dialysis , vasopressor agent . Patients know hypersensitivity drug use study class , excipients . Pregnant nursing ( lactate ) female patient , pregnancy define state female conception termination gestation , confirm positive Î²HCG laboratory test ( &gt; 9 mIU/mL ) Baseline . Female patient childbearing potential , defined woman physiologically capable become pregnant , UNLESS agree abstinence sexual activity .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Paediatric liver transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Reduced calcineurin inhibitor</keyword>
	<keyword>Cyclosporine , tacrolimus</keyword>
	<keyword>Renal function</keyword>
	<keyword>Composite efficacy endpoint ( treat biopsy proven acute rejection death , graft loss )</keyword>
	<keyword>Liver transplant</keyword>
</DOC>